1 November 2019
Ladies and gentleman,
On behalf of the Board, as Chairman I would like to welcome you to Immutep’s Annual General Meeting for 2019.
Immutep is an Australian biotech that has established its leadership in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Our technologies originate from our strong intellectual property around the LAG-3 immune control mechanism, which was discovered by our Chief Scientific Officer and Chief Medical Officer, Dr Frederic Triebel, who is here with us today.
For further information please download the attached PDF:
Download this document
